Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic
• Slate Medicines’ antibody drug is designed to block PACAP, a protein associated with migraines. • The Phase 1-ready asset was licensed from China-based DartsBio Pharmaceuticals.